The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?

Mizdrak M, Batistić D, Mizdrak I

Open source

DOI
10.3390/medsci14050577
Published
2026 Sep 17
Container
Medical sciences (Basel, Switzerland)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/medsci14050577,
  title = {The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?},
  author = {Mizdrak M and Batistić D and Mizdrak I},
  year = {2026},
  journal = {Medical sciences (Basel, Switzerland)},
  doi = {10.3390/medsci14050577},
  url = {https://doi.org/10.3390/medsci14050577}
}

RIS

TY  - JOUR
TI  - The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
AU  - Mizdrak M
AU  - Batistić D
AU  - Mizdrak I
PY  - 2026
JO  - Medical sciences (Basel, Switzerland)
DO  - 10.3390/medsci14050577
UR  - https://doi.org/10.3390/medsci14050577
ER  - 

APA

M, M., D, B., & I, M. (2026). The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?. Medical sciences (Basel, Switzerland). https://doi.org/10.3390/medsci14050577

Source records